A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Linerixibat (Primary)
- Indications Primary biliary cirrhosis; Pruritus
- Focus Registrational; Therapeutic Use
- Acronyms GLISTEN
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
Most Recent Events
- 07 Nov 2025 According to the GSK media release, data from this study to be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place in Washington D.C., from 7 to 11 November.
- 26 Feb 2025 Status changed from active, no longer recruiting to completed.
- 01 Oct 2024 This study has been completed in Greece.